This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

ADMA Biologics Inc
11/4/2026
Good afternoon and welcome to ADMA Biologics third quarter 2026 financial results and business update conference call on Wednesday, November 4th, 2026. At this time, all participants are in a listen only mode. There will be a question and answer session to follow. Please be advised that this call is being recorded at the company's request and will be available on the company's website approximately two hours following the end of the call. At this time, I would like to introduce the company. Please go ahead.
Welcome, everyone, and thank you for joining us this afternoon to discuss Adena Biologics' financial results for the third quarter of 2026 and recent corporate updates. I am joined today by Adam Grossman, our President and Chief Executive Officer, and Terri Kohler, our Chief Financial Officer and Treasurer. During today's call, Adam will provide some introductory comments and provide an update on corporate progress, and Terry will provide an overview of the company's third quarter 2026 financial results. Finally, Adam will then provide some brief summary remarks before opening the call up for questions. Earlier today, we issued a press release detailing our third quarter 2026 financial results, achievements, and recent corporate updates. The release is available on our website at www.admobiologics.com. Before we begin our formal comments, I'll remind you that we will be making forward-looking statements during today's call that represent the company's intentions, expectations, or beliefs concerning future events which constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to factors, risks, and uncertainties, such as those detailed in today's press release announcing this call and in our filings with the SEC, which may cause actual results to differ materially from the results expressed or implied by such statements. In addition, any forward-looking statements represent our views only as of the date of this call and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligations to update any such statements except as required by the federal security laws. We refer you to the Disclosures Notice section in our earnings release we issued today and the Risk Factors section in our quarterly report on Form 10-Q for the quarter ended September 30th, 2026 for discussion of the important factors that could cause actual results to differ materially from these forward-looking statements. Please note the discussion on today's call includes certain non-GAAP financial measures, including adjusted EBITDA, adjusted net income, and adjusted basic EPS. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP metric is available in our earnings release, which is available on our website at www.admobiologics.com. With that, I would now like to turn the call over to Adam Grossman.
Adam? Thank you. Good afternoon, everyone. And thank you for joining us. Our third quarter performance highlights two key items. First, we are seeing accelerating incentive demand. And second, we are demonstrating our ability to translate commercial momentum into substantial earnings growth. Favorable product mix, yield enhanced manufacturing, and disciplined execution are driving expanding profitability and meaningful earnings per share growth. We believe these two facts show the enduring strength of our business and ability to create value for stockholders. Ascent of revenue reached 124.7 million, increasing 31% year over year and 21% sequentially. Total revenue grew 13% sequentially to 141.1 million, and corporate gross margin reached 71%. Year-to-date through September 30, 2026, the company has repurchased 16.5 million shares, representing approximately 6.3% of the shares outstanding at year-end 2025. We continue to execute against our previously reported target of $200 million or more in total share repurchases during 2026. Terry will review the financial results in our capital allocation strategy in greater detail shortly. Ascendant's momentum reflects underlying patient demand supported by broader physician adoption, new patient starts, and increasing end user utilization. Favorable distributor reported pull through continued into the fourth quarter, providing further confidence in the durability of Ascendant's growth trajectory. We continue to experience strong momentum within the primary immunodeficiency patient population, where sustained growth in Ascendant's utilization is contributing to an increasingly durable and expanding foundation of recurring patient demand. Importantly, we believe significant additional growth opportunities remain within secondary immunodeficiency patient populations, where recent growth has been moderate. However, we believe this population represents a potentially meaningful and largely untapped opportunity for incentives. As awareness of Ascendant's differentiated clinical profile continues to expand among treating physicians, supported by our focused medical education and commercial initiatives, coupled with the growing body of scientific evidence, we are optimistic that adoption within these patient populations could accelerate in coming periods, providing a potential additional catalyst for sustained long-term product growth. We believe Ascenta remains early in its penetration of later line refractory and medically complex primary immunodeficiency patients. Its differentiated profile expanding clinical evidence base support a significant long-term commercial opportunity. Turning to Bibigam, third quarter revenue was 15.4 million compared with 19.4 million in the second quarter as standard IG pricing and competitive pressures persisted. While reported Vivigam revenue declined sequentially, underlying end-user utilization showed encouraging signs of stabilization entering into the fourth quarter. We continue to prioritize sustainable commercial participation rather than matching aggressive competitor rebating and discounting. Our strategies reflect the distinct opportunities for each product. Expanding incentives adoption through clinical engagement and real-world health outcomes evidence. while supporting Bibigam through discipline contracting, manufacturing quality, and product-specific scientific differentiation. Our scientific evidence base continues to expand. At the upcoming ACAAI annual conference in November, we will be presenting real-world health outcomes data from 127 medically complex primary immunodeficiency patients. Most of whom had previously received other immunoglobulin therapies. Comparing the 12 months before and after incentive initiation, the analysis identified statistically significant reductions in infection-related hospitalizations, outpatient healthcare utilization, oral antibiotic use, and corticosteroid use. These findings add important evidence to physician and payer discussions regarding incentives role in treating appropriate patients. recently published peer-reviewed research examining thrombosis-related product attributes represents an important advancement in ADMA's scientific differentiation strategy, with particular relevance to Bibigam's competitive positioning in the U.S. standard immune globulin market. As healthcare providers increasingly evaluate product quality, manufacturing consistency, and safety-related attributes alongside pricing and access, we believe these findings provide objective scientific evidence to support informed product evaluations and establish a more rigorous framework for assessing clotting-related activity and potential thrombotic risk across immune globulin products. We believe the totality of these data underscores the strength of ADMIS manufacturing capabilities, enhances our commercial education efforts, and provide an additional point of differentiation for Bibigam. We anticipate that scientific evidence will improve BIVIGAM's positioning in the competitive standard US IG market, and this growing body of evidence will contribute to continued utilization, stabilization, and potential revenue growth for BIVIGAM in the coming periods. During the third quarter, we advanced SG001, our investigational pneumococcal hyperimmune globulin candidate, through preclinical assay development and manufacturing readiness activities. Admolytics, our proprietary AI platform, has helped accelerate SGL01's development by using computational modeling, artificial intelligence, and predictive analytics to forecast final titer values from limited experimental data. We believe this capital-efficient and data-driven approach can improve analytical efficiency and reduce laboratory testing requirements as we pursue SGL01's development using our established processes. Additionally, we are encouraged by the constructive FDA feedback the company received in late October on our SG-001 pre-IND meeting package, which we believe represents an important milestone for the pipeline program. Notably, we received constructive feedback from the FDA regarding the proposed clinical development strategy, including key elements of the planned clinical study. Based on the FDA's feedback, we intend to incorporate the recommendations into the final clinical protocol and advance preparations for an IMD submission. The FDA also indicated that our proposed assay would be acceptable for product testing subject to appropriate validation. Collectively, we believe this regulatory feedback supports advancing this program forward with a potentially efficient development pathway that leverages ADMA's established manufacturing capabilities and clinical development experience as we move SGO01 towards a registrational clinical trial. We continue to believe SGO01 represents a potential $300 to $500 million annual revenue opportunity, and we will continue to keep investors informed as the program progresses in the normal and ordinary course. We are reiterating our full-year revenue guidance of at least $530 million and increasing our minimum expectations for adjusted EBITDA and adjusted net income. We believe continued ascended momentum, disciplined Thank you, Adam. I'll review our third quarter financial results, cash generation, and capital allocation.
You're reading a preview of the ADMA Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing